{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-084337","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.196697+00:00","generated_at":"2026-05-30T22:48:42.478818+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CERo Therapeutics names new CFO and CDO, reprices options to $0.10","bullets":["Al Kucharchuk appointed CFO effective Oct 1, 2024; receives 500K stock options vesting over 12 months, monthly consulting fee $16K.","Kristen Pierce appointed CDO effective Oct 1, 2024; receives 200K options vesting over 24 months (50% accelerated on FDA IND acceptance), $30K/mo fee.","Chris Ehrlich named Interim CEO; receives 2.8M options vesting 50% on IND and 50% on $1.5M financing, $30K/mo fee.","All outstanding options with exercise price >$0.10 repriced to $0.10 per share under 2024 Equity Incentive Plan.","Brian Atwood (ex-CEO) and Charles Carter (ex-CFO) enter consulting agreements; Atwood forfeits 1.33M options, Carter forfeits 495K options."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-084337","json":"https://secwatch.observer/filing/0001213900-24-084337.json","markdown":"https://secwatch.observer/filing/0001213900-24-084337.md","text":"https://secwatch.observer/filing/0001213900-24-084337.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024084337/0001213900-24-084337-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024084337/ea0216216-8k_cero.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T22:48:42.478818+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04dac54f9a","claim":"Charles R. Carter resigned as Chief Financial Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"As previously announced, Charles R. Carter resigned from his position as Chief Financial Officer, effective on September 30, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024084337/0001213900-24-084337-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"6f838387cd","claim":"Andrew Albert \"Al\" Kucharchuk was appointed as Chief Financial Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"On September 30, 2024, the Board appointed Andrew Albert “Al” Kucharchuk as Chief Financial Officer of the Company, effective October 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024084337/0001213900-24-084337-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"c0d01b949f","claim":"Kristen Pierce was appointed as Chief Development Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"On September 30, 2024, the Board of Directors (the “ Board ”) of CERo Therapeutics Holdings, Inc. (the “ Company ”) appointed Kristen Pierce, Ph.D., as Chief Development Officer of the Company, effective October 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024084337/0001213900-24-084337-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Development Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}